Laches Defense No Longer Available in ASBCA Appeals
Client Alert | 1 min read | 07.08.21
In Lockheed Martin Aeronautics Company, ASBCA No. 62209 (a C&M case), the Board granted Lockheed Martin’s motion for summary judgment on the issue of whether the Government can assert laches as an affirmative defense to a Contract Disputes Act claim. In a case of first impression, Lockheed Martin argued that the affirmative defense of laches is not available in CDA appeals because laches is an equitable doctrine, which may not be applied when there is an applicable statute of limitations, such as the CDA’s six-year statute of limitations. The Air Force argued that FAR 33.203(c) preserves the equitable defense of laches because the clause states that the Boards of Contract Appeals “continue to have all of the authority they possessed before the Disputes statute with respect to disputes arising under a contract, as well as authority to decide disputes relating to a contract.” The Board held that, consistent with the U.S. Supreme Court’s decisions in SCA Hygiene Prods. Aktiebolag v. First Quality Baby Prods., LLC, 137 S. Ct. 954 (2017) (a patent case) and Petrella v. Metro-Goldwyn-Mayer, Inc., 572 U.S. 663 (2014) (a copyright infringement case), laches is not available when there is a “legislatively-enacted statute of limitations,” and FAR 33.203(c) does not preserve the pre-FASA affirmative defense of laches. The Board noted that while the Federal Circuit has not yet applied SCA Hygiene in a CDA case, the Board is bound by the precedent of the United States Supreme Court, and therefore does not need to await a Federal Circuit decision.
The Board’s decision in Lockheed Martin Aeronautics Company marks the end of laches as an affirmative defense to claims brought within the CDA’s six-year statute of limitations at the ASBCA.
Contacts
Insights
Client Alert | 5 min read | 12.12.25
Eleventh Circuit Hears Argument on False Claims Act Qui Tam Constitutionality
On the morning of December 12, 2025, the Eleventh Circuit heard argument in United States ex rel. Zafirov v. Florida Medical Associates, LLC, et al., No. 24-13581 (11th Cir. 2025). This case concerns the constitutionality of the False Claims Act (FCA) qui tam provisions and a groundbreaking September 2024 opinion in which the United States District Court for the Middle District of Florida held that the FCA’s qui tam provisions were unconstitutional under Article II. See United States ex rel. Zafirov v. Fla. Med. Assocs., LLC, 751 F. Supp. 3d 1293 (M.D. Fla. 2024). That decision, penned by District Judge Kathryn Kimball Mizelle, was the first success story for a legal theory that has been gaining steam ever since Justices Thomas, Barrett, and Kavanaugh indicated they would be willing to consider arguments about the constitutionality of the qui tam provisions in U.S. ex rel. Polansky v. Exec. Health Res., 599 U.S. 419 (2023). In her opinion, Judge Mizelle held (1) qui tam relators are officers of the U.S. who must be appointed under the Appointments Clause; and (2) historical practice treating qui tam and similar relators as less than “officers” for constitutional purposes was not enough to save the qui tam provisions from the fundamental Article II infirmity the court identified. That ruling was appealed and, after full briefing, including by the government and a bevy of amici, the litigants stepped up to the plate this morning for oral argument.
Client Alert | 8 min read | 12.11.25
Director Squires Revamps the Workings of the U.S. Patent Office
Client Alert | 8 min read | 12.10.25
Creativity You Can Use: CJEU Clarifies Copyright for Applied Art
Client Alert | 4 min read | 12.10.25
Federal Court Strikes Down Interior Order Suspending Wind Energy Development





